Lupin Limited Expands into Chinese Market with Oseltamivir Approval

Global pharmaceutical company Lupin Limited has officially entered the Chinese market, marking a significant milestone in its international expansion strategy. On May 22, 2026, the company announced that China’s National Medical Products Administration approved its abbreviated new drug application for Oseltamivir phosphate oral suspension. This regulatory clearance was achieved in partnership with Yabao Pharmaceuticals, a company recognized for its established presence in the Chinese pediatric medicine sector.

Strategic Partnership to Enhance Pediatric Care

The introduction of Oseltamivir phosphate oral suspension (6 mg/ml) is designed to improve access to essential treatments for influenza. The medication is indicated for the treatment of influenza A and B in patients as young as two weeks old and for the prophylaxis of influenza A and B in individuals aged one year and older.

For Lupin, this move represents a calculated entry into one of the world’s largest pharmaceutical markets. Fabrice Egros, Head of Corporate Development at Lupin, described the approval as a strategic step that reflects the company’s commitment to providing high-quality, affordable therapies, particularly within pediatric healthcare. Similarly, Wei Ren, President of Yabao, emphasized that the collaboration highlights a shared dedication to advancing pediatric medicine and strengthening the companies’ joint capabilities in clinical and regulatory affairs.

About the Companies

Lupin Limited

Headquartered in Mumbai, India, Lupin is a global pharmaceutical firm with a footprint spanning over 100 markets. The company’s portfolio includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With 15 manufacturing facilities and 7 research centers worldwide, Lupin focuses on therapeutic areas including cardiovascular health, diabetes, respiratory diseases, and the central nervous system.

Yabao Pharmaceutical Co.

Yabao Pharmaceutical (SSE: 600351) is a China-based company with integrated capabilities in development, manufacturing, and marketing. While historically focused on traditional Chinese medicine and chemical generics, Yabao is currently expanding its portfolio to include innovative drug development. The company maintains cGMP-compliant manufacturing sites, including facilities approved by the U.S. Food and Drug Administration (FDA) and European regulatory bodies.

Key Takeaways

• Market Entry: Lupin has officially launched its first product in China following regulatory approval from the National Medical Products Administration.
• Clinical Focus: The approved Oseltamivir phosphate oral suspension is specifically targeted toward pediatric influenza treatment and prophylaxis.
• Collaborative Effort: The launch is supported by a partnership with Yabao Pharmaceuticals, leveraging Yabao’s deep experience in the Chinese domestic market.
• Global Reach: This development aligns with Lupin’s broader objective of scaling its operations across major international pharmaceutical markets.

As Lupin continues to integrate its operations into the Chinese healthcare landscape, the partnership with Yabao is expected to serve as a foundation for further research and development initiatives aimed at addressing chronic conditions for both pediatric and adult populations.